AcelRx Pharmaceuticals, Inc. (ACRX)
| Market Cap | 189.68M |
| Revenue (ttm) | 5.15M |
| Net Income (ttm) | -45.88M |
| Shares Out | 87.91M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $1.91 |
| Previous Close | $1.91 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.90 |
| Day's Range | 1.81 - 1.92 |
| Day's Volume | 6,367,054 |
| 52-Week Range | 0.76 - 2.35 |
The company announced the pricing of a public stock offering.
REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...
Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.
REDWOOD CITY, Calif., Dec. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovati...
REDWOOD CITY, Calif., Dec. 9, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovativ...
REDWOOD CITY, Calif., Dec. 4, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovativ...
Acelrx shares plummeted after the company released third quarter earnings. However, numbers were significantly up compared to any prior period.
REDWOOD CITY, Calif., Nov. 6, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovativ...
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2020 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -42.86% and -77.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead ...
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AcelRx (ACRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.
REDWOOD CITY, Calif., Sept. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization ...
REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
ACRX Shareholders had a lot to digest during the past three months, including capital raise, cancelled and new marketing agreements, and the exit from the Tetraphase bidding war.
AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2020 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 42.86% and -25.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...
REDWOOD CITY, Calif., Aug. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., June 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of ...
REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovativ...
AcelRx Pharmaceuticals: Finally Light At The End Of The Tunnel
AcelRx Pharmaceuticals: Lean Back And Watch The Rocket Launch
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2020 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -33.33% and -85.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...
AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AcelRx Pharmaceuticals (ACRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
As of late, it has definitely been a great time to be an investor in AcelRx Pharmaceuticals.
After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as ...
AcelRx Acquiring Tetraphase, And Other News: The Good, Bad And Ugly Of Biopharma
AcelRx Pharmaceuticals, Inc.'s (ACRX) CEO Vince Angotti on Q4 2019 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (NASDAQ:ACRX) reported Q4 results. Quarterly Results Earnings per share increased 100% over the past year to ($0.18), which beat the estimate of ($0.20).
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.
In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.73, marking a -1.14% move from the previous day.
In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.91, marking a -0.78% move from the previous day.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ne...
Top Ranked Momentum Stocks to Buy for January 3rd
The market potential for ACRX is massive and thus the stock at current levels – despite cash management challenges – could provide investors with significant opportunities.
AcelRx Pharmaceuticals, Inc. (ACRX) has been struggling lately, but the selling pressure may be coming to an end soon.
AcelRx Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
About ACRX
AcelRx Pharmaceuticals, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx ... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Feb 14, 2011 |
| CEO Vincent Angotti | Employees 99 |
| Stock Exchange NASDAQ | Ticker Symbol ACRX |
Financial Performance
In 2019, ACRX's revenue was $2.29 million, an increase of 6.42% compared to the previous year's $2.15 million. Losses were -$53.24 million, 12.9% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 5.46, which is an increase of 185.86% from the latest price.